893 related articles for article (PubMed ID: 29945808)
61. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
[TBL] [Abstract][Full Text] [Related]
62. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation.
Yagishita A; Takahashi Y; Takahashi A; Fujii A; Kusa S; Fujino T; Nozato T; Kuwahara T; Hirao K; Isobe M
Circ J; 2011; 75(10):2343-9. PubMed ID: 21778595
[TBL] [Abstract][Full Text] [Related]
63. Uninterrupted or Minimally Interrupted Direct Oral Anticoagulant Therapy is a Safe Alternative to Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation: An Updated Meta-Analysis.
Ottóffy M; Mátrai P; Farkas N; Hegyi P; Czopf L; Márta K; Garami A; Balaskó M; Pótóné-Oláh E; Mikó A; Rostás I; Wobbe B; Habon T
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987707
[TBL] [Abstract][Full Text] [Related]
64. Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review.
Vrachatis DA; Giannopoulos G; Kossyvakis C; Panagopoulou V; Vavuranakis M; Papaioannou TG; Pagoni S; Pyrgakis VN; Cleman MW; Deftereos SG
Curr Pharm Des; 2017; 23(9):1334-1345. PubMed ID: 27917710
[TBL] [Abstract][Full Text] [Related]
65. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis.
Van Der Meersch H; De Bacquer D; De Vriese AS
Am Heart J; 2017 Feb; 184():37-46. PubMed ID: 27892885
[TBL] [Abstract][Full Text] [Related]
66. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation.
Trujillo TC; Dobesh PP; Crossley GH; Finks SW
Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542
[TBL] [Abstract][Full Text] [Related]
67. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta-analysis.
Romero J; Cerrud-Rodriguez RC; Diaz JC; Rodriguez D; Arshad S; Alviz I; Cerna L; Rios S; Monhanty S; Natale A; Garcia MJ; Di Biase L
J Cardiovasc Electrophysiol; 2019 Aug; 30(8):1250-1257. PubMed ID: 31257677
[TBL] [Abstract][Full Text] [Related]
68. Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study.
Camm AJ; Turpie AGG; Hess S; Amarenco P; Lambelet M; Haas S; van Eickels M; Kirchhof P;
Europace; 2018 Jun; 20(6):e87-e95. PubMed ID: 29016755
[TBL] [Abstract][Full Text] [Related]
69. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation.
Mao YJ; Wang H; Huang PF
J Interv Card Electrophysiol; 2021 Apr; 60(3):407-417. PubMed ID: 32361948
[TBL] [Abstract][Full Text] [Related]
70. Anticoagulation after catheter ablation of atrial fibrillation guided by implantable cardiac monitors.
Zuern CS; Kilias A; Berlitz P; Seizer P; Gramlich M; Müller K; Duckheim M; Gawaz M; Schreieck J
Pacing Clin Electrophysiol; 2015 Jun; 38(6):688-93. PubMed ID: 25753968
[TBL] [Abstract][Full Text] [Related]
71. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark.
Karasoy D; Gislason GH; Hansen J; Johannessen A; Køber L; Hvidtfeldt M; Özcan C; Torp-Pedersen C; Hansen ML
Eur Heart J; 2015 Feb; 36(5):307-14a. PubMed ID: 25368205
[TBL] [Abstract][Full Text] [Related]
72. Uninterrupted versus interrupted direct oral anticoagulation for catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Asad ZUA; Akhtar KH; Jafry AH; Khan MH; Khan MS; Munir MB; Lakkireddy DR; Gopinathannair R
J Cardiovasc Electrophysiol; 2021 Jul; 32(7):1995-2004. PubMed ID: 33861494
[TBL] [Abstract][Full Text] [Related]
73. Thromboembolic Risk of Cessation of Oral Anticoagulation Post Catheter Ablation in Patients With and Without Atrial Fibrillation Recurrence.
Rong B; Han W; Lin M; Hao L; Zhang K; Chen T; Sha R; Wang J; Wang R; Zhong J
Am J Cardiol; 2020 Dec; 137():55-62. PubMed ID: 33002462
[TBL] [Abstract][Full Text] [Related]
74. Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis.
Lu D; Zhang Q; Liu Q; Wang K; Wang S; Shan Q
J Interv Card Electrophysiol; 2015 Nov; 44(2):105-11. PubMed ID: 26342485
[TBL] [Abstract][Full Text] [Related]
75. Long-term aspirin does not lower risk of stroke and increases bleeding risk in low-risk atrial fibrillation ablation patients.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler DO MJ; Day JD; Mallender C; Osborn JS; Weiss JP; Bunch TJ
J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1241-1246. PubMed ID: 28845890
[TBL] [Abstract][Full Text] [Related]
76. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
[TBL] [Abstract][Full Text] [Related]
77. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis.
Bin Abdulhak AA; Khan AR; Tleyjeh IM; Spertus JA; Sanders SU; Steigerwalt KE; Garbati MA; Bahmaid RA; Wimmer AP
Europace; 2013 Oct; 15(10):1412-20. PubMed ID: 23954918
[TBL] [Abstract][Full Text] [Related]
78. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression.
Briceno DF; Villablanca PA; Lupercio F; Kargoli F; Jagannath A; Londono A; Patel J; Otusanya O; Brevik J; Maraboto C; Berardi C; Krumerman A; Palma E; Kim SG; Natale A; DI Biase L
J Cardiovasc Electrophysiol; 2016 Jun; 27(6):683-93. PubMed ID: 27004444
[TBL] [Abstract][Full Text] [Related]
79. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
[TBL] [Abstract][Full Text] [Related]
80. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
